Assertio Holdings stock (traded under the ticker symbol ASRT on the Nasdaq Global Market) experienced significant long-term downward valuation pressures, prompting corporate actions such as reverse stock splits to maintain exchange listing compliance. Subsequently, following an acquisition agreement, Zydus Lifesciences completed a cash tender offer to acquire Assertio, making it a wholly-owned subsidiary and resulting in the delisting of ASRT stock from public exchanges.